As a treating physician who also serves as the Chairman of the Alliance for Safe Biologic Medicines (ASBM), I have been watching with great interest as the Food and Drug Administration (FDA) begins to unveil the approach it will take to bring “biosimilar” medications to the US.  Biosimilars are attempts to replicate brand name biologic medicines. But as the name indicates, they are similar to them but not identical.   Interestingly, ...

Read more...

1 Pages

Most Popular

✓ Join 150,000+ subscribers
✓ Get KevinMD's most popular stories